BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 21950731)

  • 1. Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature.
    Hughes IP; Harris M; Choong CS; Ambler G; Cutfield W; Hofman P; Cowell CT; Werther G; Cotterill A; Davies PS;
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):62-71. PubMed ID: 21950731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?
    Colmenares A; González L; Gunczler P; Lanes R
    J Pediatr Endocrinol Metab; 2012; 25(7-8):651-7. PubMed ID: 23155689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polymorphism in the leptin receptor gene at position 223 is associated with growth hormone replacement therapy responsiveness in idiopathic short stature and growth hormone deficiency patients.
    Su PH; Yang SF; Yu JS; Chen SJ; Chen JY
    Eur J Med Genet; 2012 Dec; 55(12):682-7. PubMed ID: 23009903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.
    Ranke MB; Lindberg A; Price DA; Darendeliler F; Albertsson-Wikland K; Wilton P; Reiter EO;
    Horm Res; 2007; 68(2):53-62. PubMed ID: 17228181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.
    Högler W; Briody J; Moore B; Lu PW; Cowell CT
    Bone; 2005 Nov; 37(5):642-50. PubMed ID: 16139578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone responsiveness: peak stimulated growth hormone levels and other variables in idiopathic short stature (ISS): data from the National Cooperative Growth Study.
    Moore WV; Dana K; Frane J; Lippe B
    Pediatr Endocrinol Rev; 2008 Sep; 6(1):5-8. PubMed ID: 18806719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An auxology-based growth hormone program: update on the Australian experience.
    Werther GA; Wang M; Cowell CT
    J Pediatr Endocrinol Metab; 2003 May; 16 Suppl 3():613-8. PubMed ID: 12795362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database).
    Darendeliler F; Ranke MB; Bakker B; Lindberg A; Cowell CT; Albertsson-Wikland K; Reiter EO; Price DA
    Horm Res; 2005; 63(1):40-7. PubMed ID: 15627781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of growth hormone treatment on height in children with idiopathic short stature.
    Jeong HR; Shim YS; Lee HS; Hwang JS
    J Pediatr Endocrinol Metab; 2014 Jul; 27(7-8):629-33. PubMed ID: 24810558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.
    Kriström B; Aronson AS; Dahlgren J; Gustafsson J; Halldin M; Ivarsson SA; Nilsson NO; Svensson J; Tuvemo T; Albertsson-Wikland K
    J Clin Endocrinol Metab; 2009 Feb; 94(2):483-90. PubMed ID: 19001519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect.
    Wit JM; Rekers-Mombarg LT; Cutler GB; Crowe B; Beck TJ; Roberts K; Gill A; Chaussain JL; Frisch H; Yturriaga R; Attanasio AF
    J Pediatr; 2005 Jan; 146(1):45-53. PubMed ID: 15644821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth Hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency.
    Wan L; Chen WC; Tsai Y; Kao YT; Hsieh YY; Lee CC; Tsai CH; Chen CP; Tsai FJ
    Pediatr Res; 2007 Dec; 62(6):735-40. PubMed ID: 17957148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children.
    Cohen P; Germak J; Rogol AD; Weng W; Kappelgaard AM; Rosenfeld RG;
    J Clin Endocrinol Metab; 2010 May; 95(5):2089-98. PubMed ID: 20207829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone treatment in prepubertal children with celiac disease and growth hormone deficiency.
    Giovenale D; Meazza C; Cardinale GM; Farinelli E; Mastrangelo C; Messini B; Citro G; Del Vecchio M; Di Maio S; Possenti I; Bozzola M
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):433-7. PubMed ID: 18030209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone use in the treatment of idiopathic short stature.
    Zucchini S
    Curr Opin Investig Drugs; 2008 Apr; 9(4):396-401. PubMed ID: 18393106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in serum GH cut-off values for pharmacological tests of GH secretion depend on the serum GH method. Clinical validation from the growth velocity score during the first year of treatment.
    Chaler EA; Rivarola MA; Guerci B; Ciaccio M; Costanzo M; Travaglino P; Maceiras M; Pagani S; Meazza C; Bozzola E; Barberi S; Bozzola M; Belgorosky A
    Horm Res; 2006; 66(5):231-5. PubMed ID: 16912509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
    Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.
    Al Shaikh A; Daftardar H; Alghamdi AA; Jamjoom M; Awidah S; Ahmed ME; Soliman AT
    Acta Biomed; 2020 Mar; 91(1):29-40. PubMed ID: 32191651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children.
    Bakker B; Frane J; Anhalt H; Lippe B; Rosenfeld RG
    J Clin Endocrinol Metab; 2008 Feb; 93(2):352-7. PubMed ID: 18000092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature.
    Gascoin-Lachambre G; Trivin C; Brauner R; Souberbielle JC
    Growth Horm IGF Res; 2007 Jun; 17(3):194-200. PubMed ID: 17321775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.